| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2010-04-12 | Almac Group (UK) MRC (UK) Merck KGaA (Germany) |
assessment of markers of response to cetuximab therapy / metastatic colorectal cancer | R&D other |
See details |
| 2010-04-12 | PregLem (Switzerland) HRA Pharma (France) |
ulipristal acetate / benign gynaecological disorders | commercialization/ distribution development marketing/ promotion |
See details |
| 2010-04-12 | Naval Medical Research Center (NMRC - USA) Sanofi Pasteur (France) |
vaccine against enterotoxigenic Escherichia coli (ETEC) / travelers' diarrhea | R&D licensing |
See details |
| 2010-04-08 | Swedish Orphan Biovitrum (Sweden) LFB (France) |
Willfact® (plasma derived human von Willebrand factor (vWF) concentrate) | commercialization/ distribution |
See details |
| 2010-04-08 | CureDM (USA) Sanofi-Aventis (France) |
Pancreate®(proisletide acetate) This first-in-class human peptide (HIP-2B) sequence of a naturally occurring human protein stimulates the formation of functional insulin producing neo-islets from pancreatic progenitor cells. / type 1 and type 2 diabetes. |
licensing manufacturing commercialization/ distribution development marketing/ promotion |
See details |
| 2010-04-08 | Galapagos (Belgium) Bausch & Lomb (USA) |
/ ophthalmic diseases |
licensing |
See details |
| 2010-04-08 | Debiopharm (Switzerland) Biocartis (Switzerland) |
companion diagnostics / oncology, infectious diseases | R&D other |
See details |
| 2010-04-07 | Domainex (UK) The Institute of Cancer Research (UK) |
lead optimisation services to find a new treatment for breast cancer. This new treatment is based on drug-like compounds that inhibit an enzyme from the PARP superfamily, whose expression leads to the survival of breast cancer cells. / breast cancer |
R&D other |
See details |
| 2010-04-06 | BioAlliance Pharma (France) Therabel Group (France) |
Loramyc® and Setofilm® / |
commercialization/ distribution other |
See details |
| 2010-04-06 | Crucell (The Netherlands) GSK Biologicals (Belgium - UK) |
malaria vaccine Ad35-CS / malaria | R&D development |
See details |
| 2010-03-31 | Isis Pharmaceuticals (USA) GSK (UK) |
antisense therapies / rare diseases, infectious diseases | R&D licensing commercialization/ distribution development |
See details |
| 2010-03-31 | Source BioScience (UK) AstraZeneca (UK) |
companion diagnostic genetic testing service / lung cancer | other |
See details |
| 2010-03-30 | Dicerna Pharmaceuticals (USA) Ipsen (France) |
RNAi therapeutics (conjugates of DsiRNA molecules and peptide targeting vectors) DsiRNA (Dicer Substrate RNAi) are based on a critical enzyme involved in the RNAi gene silencing cascade, Dicer. This enzyme acts earlier in the pathway, preparing double-stranded RNA for processing. Dicer then hands off these small RNA molecules to the mature gene silencing complex (RISC). Dicerna’s molecules are 25 or more base pairs in length and take advantage of this natural and early entry point. / oncology and endocrinology |
R&D development |
See details |
| 2010-03-26 | Actelion (Switzerland) Invida (Singapore) |
Tracleer® (bosentan) / pulmonary arterial hypertension (PAH) | commercialization/ distribution |
See details |
| 2010-03-25 | Cellectis (France) Boehringer Ingelheim (Germany) |
homologous recombination patents |
licensing |
See details |
